Bilal Kovan

Bilal Kovan

Auto-generated profile, based on publicly available information

Bilal Kovan

Istanbul University, Istanbul Faculty of Medicine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ETEdanur Topal
Edanur Topal
BKBilal Kovan
Bilal Kovan
AÇAyça İribaş çelik
Ayça İribaş çelik
SKSerkan Kuyumcu
Serkan Kuyumcu
MBMert Basaran
Mert Basaran
YSYasemin Sanli
Yasemin Sanli
Purpose: This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [177Lu] Lu-PSMA − 617 therapy. Methods: The study included 110 patients who received ≥ 4 cycles of [177Lu] Lu-PSMA − 617 therapy. Whole-body static and abdominal SPECT-CT imaging was performed at 4, 24, and 96 h post-administration. Kidney function was assessed using dynamic renal scintigraphy and biochemical tests conducted prior to treatment. Estimated glomerular filtration rate (eGFR) levels were calculated using the CKD-EPI formula before each treatment cycle and at the 6th week post-treatment. Results: Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (p >.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (p >.05). Among patients reaching a cRD of 23 Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (p <.05). Of the 13 patients exceeding cRD of 28 Gy, five maintained CKD-EPI levels above 90 mL/min/1.73 m2 post-treatment. Conclusion: Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [177Lu] Lu-PSMA-617 therapy with manageable nephrotoxicity. Considering the significant inter-patient variability, establishing universal absorbed dose-response relationships remains challenging. Prospective multicenter studies are crucial to refining toxicity thresholds and advancing tailored treatment strategies to optimize safety and efficacy.

10 November 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DSDuygu Has Simsek
Duygu Has Simsek
YGYunus Guzel
Yunus Guzel
DDDilara Denizmen
Dilara Denizmen
YSYasemin Sanli
Yasemin Sanli
FBFikret Buyukkaya
Fikret Buyukkaya
SKSerkan Kuyumcu
Serkan Kuyumcu

26 August 2020 in Nuclear Medicine Seminars
Verified
Journal Article
Closed access
YPYasemin Parlak
Yasemin Parlak
BUBağnu Uysal
Bağnu Uysal
FKF. Suna Kıraç
F. Suna Kıraç
BKBilal Kovan
Bilal Kovan
MDMustafa Demir
Mustafa Demir
SDSemra Dönmez
Semra Dönmez

17 June 2023 in Radiation Protection Dosimetry
Verified
Journal Article
Open access
PDF file
BKBilal Kovan
Bilal Kovan
BDBayram Demir
Bayram Demir
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
DSDuygu Has Simsek
Duygu Has Simsek
ZÖZeynep Gözde Özkan
Zeynep Gözde Özkan
YSYasemin Sanli
Yasemin Sanli
The aim of this study is to create an inhomogeneous human-like phantom, whose attenuation and scattering effects are similar to the human body, as an alternative to the homogeneous phantoms traditionally used in calibration factor (CF) determination. The phantom was designed to include the thorax, abdomen and upper pelvis regions sized to represent a 75-kg male with a body mass index of 25. Measurements using Lu-177 with 50- and 100-mL lesion volumes were performed using inhomogeneous anthropomorphic body phantom (ABP) and homogeneous NEMA PET body phantom. There was a difference of 5.7% of Calibration Factor including attenuation and scatter effect between ABP and NEMA PET body phantom. Because it better reflects the attenuation and scatter effect, it is recommended to use a human-like inhomogeneous phantom for determination of CF instead of a homogeneous phantom.


26 October 2023 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
BKBilal Kovan
Bilal Kovan
CCCaner Civan
Caner Civan
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
DSDuygu Has Simsek
Duygu Has Simsek
ZOZeynep Gozde Ozkan
Zeynep Gozde Ozkan
SKSerkan Kuyumcu
Serkan Kuyumcu